Pharmacological agents can modify the ventricular remodelling process that occurs in myocardial infarction and heart failure.
How do various pharmacological agents affect the ventricular remodelling process in myocardial infarction and heart failure?
This review summarizes the mechanisms of ventricular remodelling following myocardial infarction and heart failure, and how pharmacological therapies can modify this process.
The mammalian left ventricle can change its size and shape in response to a variety of stimuli including loss of tissue and external work. These changes in size and shape, defined as remodelling, are the sum total of a number of processes that involve the myocyte and the interstitial fibrous structures which provide the matrix in which the myocyte functions. The adapted mechanisms which occur are affected by humoral and cellular phenomena and can be modified by pharmacological agents. This paper reviews the remodelling process that occurs in myocardial infarction and heart failure and the effect of various pharmacological agents on this remodelling process.
Sabbah et al. (Fri,) conducted a review in Myocardial infarction and heart failure. Pharmacological agents was evaluated. Pharmacological agents can modify the ventricular remodelling process that occurs in myocardial infarction and heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: